Login / Signup
Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
Fengtan Li
Xifeng Dong
Published in:
Thoracic cancer (2021)
Keyphrases
</>
advanced non small cell lung cancer
phase ii
epidermal growth factor receptor
clinical trial
phase iii
study protocol
open label
randomized controlled trial
metabolic syndrome
skeletal muscle
insulin resistance
glycemic control